Using data to drive improvement

Whether you are developing breakthrough cell therapies or optimizing how you process blood, the prospect of improving your operations can be significant. Let our expertise paired with procedural and device data provide a roadmap for moving the dial.

Start Cell Collections Strong

Ensuring the best possible starting material is critical to providing the best outcome. Your final therapy is highly dependent on the quality of your starting material. Whether you are just starting your cell therapy clinical trial or scaling up from phase 3 to commercial, the starting material collected from the patient matters. No two patients are the same and collections can vary. Controlling what you can becomes all the more important.

Variability in CAR T-cell expansion may cause the contamination of the starting peripheral blood mononuclear cell (PBMC) concentrates with monocytes (non-target cells).[1]

Minimize Product Failures

Don't let the products you collect at the beginning derail your process, and ultimately, your final therapy. Manufacturing processes may be at risk due to low collection efficiency and off-target cellular contaminants. Collected product quality could be too poor to even begin the manufacturing process.[1,2]

Managing each unique apheresis procedure ultimately affects the successful manufacture of the CAR T-cell product.[2]

Leverage Our Expertise

- Unique insight into procedural data directly from the Spectra Optia® Apheresis System
- 40 years of experience and expertise in apheresis technology and collections
- Dedicated service and support from a network of our engineers and medical science liaisons

Our Commitment

Every day, Terumo Blood and Cell Technologies helps biotech and healthcare organizations that perform apheresis.
We stand united in the goal to advance and optimize the development and delivery of cell and gene therapies for patients in need around the world.

Our Services

Spectra Optia Cell Collection Data Analysis

- Single or multiple procedure analysis
- Comprehensive analysis from pre-procedure data through final therapy results
- Optimization suggestions
- Collection site comparison and benchmarking
- On-site and off-site systems support

Spectra Optia Prediction Algorithm

- Collection data review
- Customized whole blood process calculation
- Statistical summary analysis

(V) Veda Insights

Cell collection services led by data analytics specialists who can help you unlock your collection data and identify areas of improvement.

Helping You Achieve Your Goals

| Enhanced strategy | Data-driven decisions | Visibility into the process | Optimized starting product | Achievement of therapy objectives |

Let's Get Started
Speak with one of our data analytics specialists for more details on how to unlock the potential of your starting product.

Email: BCT.CustomerSupport@terumobct.com
Learn more at terumobct.com/vedasolutions

[1] Stroncek DF, Ren J, Lee DW, et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T Cells. *Cytotherapy*. 2016;18(7):898-901.

[2] Molloy E, Conry Cantilena C, West KA. Optimzing the apheresis product. In: Chimeric Antigen Receptor T-Cell Therapies for Cancer: A Practical Guide. Elsevier; 2020: chap2. Accessed April 15, 2020. doi: https://doi.org/10.1016/B978-0-323-66181-2.00002-0.